Molecular Partners AG published the invitation to its 2026 Annual General Meeting on April 14, 2026, and proposed Clare Fisher for election to the Board of Directors while Steven H. Holtzman will not stand for re-election.
Key takeaways
Annual General Meeting scheduled for April 14, 2026, at 9:00 am CET at JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland.
Clare Fisher nominated for election to Board of Directors; currently SVP Global Business Development and M&A at BeOne Medicines.
Steven H. Holtzman, current Board member, will not stand for re-election after 12 years of service.
Clare Fisher has over two decades of experience in biotech business development, including roles at Shire plc, Kaleido, Cubist, Blueprint Medicines, and Genzyme.
Financial calendar includes Interim Management Statement Q1 2026 on May 12, 2026, and Half-year results 2026 on August 25, 2026.